Corrigendum to: “European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I” [Eur Urol 2008;53:478–96] and to: “European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part II” [Eur Urol 2008;53:497–513]
S. Krege(University of Lübeck), Ó. Leiva Galvis, Karim Fizazi(Université de Lille), Silke Gillessen(Institute of Oncology Research), Maike de Wit(Florida Hospital Cancer Institute), Annette Dieing, Kai Uwe Koehrmann, Ronald de Wit(Erasmus MC Cancer Institute), I. Bodrogi(Aarhus University Hospital), Thomas Gauler, Robert Huddart(Institute of Cancer Research), Axel Heidenreich(Centrum für Integrierte Onkologie), Gedske Daugaard(Copenhagen University Hospital), Eva Cavallin‐Ståhl(Lund University), William G. Jones(The University of Texas Health Science Center at Houston), Sabine Kliesch(University Hospital Münster), Xavier García del Muro(Institut Català d'Oncologia), Pilar Laguna(Istanbul Medipol University), Rainer Souchon, Sophie D. Fosså(Oslo University Hospital), Alan Horwich(Institute of Cancer Research), Johnathan Joffe, Michael Hartmann(Jena University Hospital), Peter Albers(Düsseldorf University Hospital), Martin Fenner(PEN American Center), C. Clemm(TUM Klinikum), Klaus‐Peter Dieckmann(Asklepios Klinik Altona), Gabriella Cohn‐Cedermark(Uppsala University Hospital), Maria De Santis(Medical University of Vienna), Carsten Bokemeyer(Universität Hamburg), Ferrán Algaba(Puigvert Foundation), Christian Kollmannsberger(BC Cancer Agency), Wolfgang Hoeltl, Lajos Géczi(National Institute of Oncology), L Kisbenedek, Johannes Claßen(St. Vincentius-Kliniken), Stéphane Culine(Radboud University Nijmegen), Olbjørn Klepp, Hans Günter Derigs(Heidelberg University), A. Gerl(Ludwig-Maximilians-Universität München), Walter Albrecht(Rudolfinerhaus Hospital), Jörg T. Hartmann(University of Tübingen), Jean-Pierre Droz, Michael Bamberg(University of Tübingen), P.H.M. de Mulder(Fondazione Vincenzo Pansadoro), Michael Jewett(Cancer Genomics Centre), Aude Fléchon(Institut Català d'Ornitologia), Markus Kuczyk, J. R. Germa-Lluch(Institut Català d'Oncologia)
Cited by 7
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
|Annals of Internal Medicine|2020|2.4k